Anti-C3b-receptor (CR1) antibodies in patients with systemic lupus erythematosus.
Using an enzyme-linked immunoadsorbent assay, IgG in the plasma and purified IgG from 2 patients with systemic lupus erythematosus (SLE) were found to strongly react with purified C3b receptor (CR1) insolubilized on microtiter plates. The amount of IgG that bound to CR1 in 201 plasma samples from 179 other patients with SLE did not significantly differ from that which bound in 72 control samples from normal individuals. Purified IgG from the patients with anti-CR1 reactivity did not inhibit CR1 function in vitro. The number of CR1 antigenic sites expressed on erythrocytes from both patients was much lower than that observed in a normal population and in the lowest range of the decreased numbers found in patients with SLE. The occurrence of anti-CR1 antibodies in patients with SLE could provide an acquired mechanism for decreased expression of CR1 through antigenic modulation of the receptor on precursor cells and/or alter the function of cells of the immune system bearing C3b receptors.
D000818:Animals; D001323:Autoantibodies / Q000032:analysis*; D006801:Humans; D007074:Immunoglobulin G / Q000032:analysis; D008180:Lupus Erythematosus, Systemic / Q000276:immunology*; D011817:Rabbits; D011951:Receptors, Complement / Q000032:analysis / Q000276:immunology*; D017463:Receptors, Complement 3b
D001323:Autoantibodies; D007074:Immunoglobulin G; D011951:Receptors, Complement; D017463:Receptors, Complement 3b